22
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Bone Marrow Transplantation in Low-Grade Non-Hodgkin's Lymphoma

Pages 199-210 | Received 05 Jun 1994, Published online: 01 Jul 2009

References

  • National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. The Non-Hodgkin Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
  • Horning S. J., Rosenberg S. A. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1984; 311: 1471–1475
  • Rohatiner A. Z. S., Lister T. A. Myeloablative therapy for follicular lymphoma. Hematol. Oncol. Clin. NA 1991; 5: 1003–1012
  • Rosenberg S. A. Validity of Ann Arbor staging of the non-Hodgkin's lymphomas. Cancer Treat. Rep. 1977; 61: 1023–1027
  • McLaughlin P., Fuller I. M., Velasquez W. S., et al. Stage HI follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J. Clin. Oncol. 1987; 5: 867–874
  • Rodgers R., McLaughlin P., Sullivan J., et al. Prognostic factors in stage IV nodular lymphoma (abstract). Proc. Am. Soc. Clin. Oncol. 1983; 2: 217
  • Young R. C., Longo D. L., Glatstein E., et al. The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment. Semin. Hematol. 1988; 25(Suppl 2)11–16
  • Portlock C. S. “Good risk” non-Hodgkin's lymphomas: approaches in management. Semin. Hematol. 1983; 20: 25–34
  • Gallagher C. J., Gregory W. M., Jones A. E., et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 1986; 4: 1470–1480
  • Weisdorf D. J., Andersen J. W., Glick J. H., Oken M. M. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J. Clin. Oncol. 1992; 10: 942–947
  • Longo D. L., Young R. C., Hubbard S. M., et al. Prolonged initial remission in patients with nodular mixed lymphoma. Ann. Intern. Med. 1984; 100: 651–656
  • Armitage J. O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med 1993; 328: 1023–1030
  • Armitage J. O., Dick F. R., Corder M. P. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat. Rep. 1992; 65: 413–418
  • Astray S., Digs C., Sutherland J. C., et al. Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival. Cancer Treat. Rep. 1981; 65: 11–12
  • Acker B., Hoppe R. T., Colby T. V., et al. Histologic conversion in the non-Hodgkin's lymphomas. J. Clin. Oncol 1983; 1: 11–16
  • Garvin A. J., Simon R. M., Osborne C. K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphoma. 192 cases from the National Cancer Institute. Cancer 1983; 52: 393–398
  • Hubbard S. M., Chabner B. A., De Vita V. T., et al. Histologic progression in non-Hodgkin's lymphoma. Blood 1982; 59: 258–264
  • Landberg T. G., Hakansson L. G., Moller T. R., et al. CVP-remission-maintenance in stage I and II non-Hodgkin's lymphomas: preliminary results of a randomized study. Cancer 1979; 44: 831–838
  • McLaughlin P., Fuller L. M., Velasquez W. S., et al. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–1602
  • Nissen N. I., Ersboll J., Hansen H. S., et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983; 52: 1–7
  • Reddy S., Saxena V. S., Pellettiere E. V., Hendrickson F. R. Early nodal and extra nodal non-Hodgkin's lymphomas. Cancer 1977; 40: 98–104
  • Richards M. A., Gregory W. M., Hall P. A., et al. Management of localized non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital 1972–1985. Haematol Oncol. 1989; 7: 1–18
  • Fisher R. I., Dahlberg S., Miller T. P., et al. Long term survival of patients with nodular histiocytic, diffuse poorly differentiated lymphocytic, diffuse mixed, and diffuse undifferentiated lymphoma treated with CHOP chemotherapy (abstract #1003). Proc. Am. Soc. Clin. Oncol. 1989; 8: 257
  • Ezdinli E. Z., Anderson J. R., Melvin F., et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J. Clin. Oncol. 1985; 3: 769–775
  • Kaufman J. H., Ezdinli E., Aungst C. W., Stutzman L. Lymphosarcoma: a comparison of extended to conservative chemotherapy. Cancer 1976; 37: 1283–1292
  • McKelvey E. M., Gottlieb I. A., Wilson H. E., et al. Hydroxyldaunomycin (Adriamycin)combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
  • Steward W. P., Crowther D., McWilliams I. J., et al. Maintenance chlorambucil after CVP in the management of advanced stage, lowgrade histologic type non-Hodgkin's lymphoma. Cancer 1988; 61: 441–447
  • Peterson B. A., Anderson J. R., Frizzera G., et al. Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML) (abstract #1004). Proc. Am. Soc. Clin. Oncol. 1990; 9: 259
  • Garcia Zueco J. C., Delgado M. P., Giraldo M. P., et al. Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients. Sangre 1992; 37: 337–344
  • Surbone A., Armitage J. O., Gale R. P. Autotransplantation in lymphoma: better therapy or healthier patients?. Ann. Intern. Med 1991; 114: 059–1060
  • Fisher R. I., Gamer E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
  • Gordon L. I., Harrington D., Andersen J., et al. Comparison of a second-generation combination chemotherapy regimen (M-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1342–1349
  • Epelbaum R., Haim N., Ben-Shahar M., et al. Dose intensity for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr. J. Med. Sci. 1988; 24: 533–537
  • DeVita V. T., Jr., Hubbard S. M., Longo D. L. The chemotherapy of lymphomas: Looking backward, moving forward-The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987; 47: 5810–5824
  • Kwak L. W., Halpem J., Olshen R. A., et al. Prognostic significance and actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J. Clin. Oncol. 1990; 8: 963–977
  • Cabanillas F., Velasquez W. S., McLaughlin P., et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin. Hematol. (suppl 2) 1988; 25: 47–50
  • Zuckerman K. S., LoBuglio A. F., Reeves J. A. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high dose doxorubicin-containing regimen. J. Clin. Oncol. 1990; 8: 248–256
  • Sweetenham J. W., Mead G. M., Whitehouse J. M. A. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 1991; 9: 2202–2209
  • Gulati S. C., Shank B., Black P., et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J. Clin. Oncol. 1988; 6: 1303–1313
  • Vose J. M., Armitage J. O., Bierman P. J., et al. Salvage therapy for relapsed or refractory non-Hodgkins' lymphoma utilizing autologous bone marrow transplantation. Am. J. Med. 1987; 87: 285–287
  • Takvorian T., Canellos G. P., Ritz J., et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N. Engl. J. Med. 1987; 87: 1499–1505
  • Goldstone A. H., Gribben J. G., McMillan A. K., et al. The sixth report of the EBMTG registry of ABMT in lymphomas (abstract). Bone Marrow Transplant 1989; 4(Suppl 2)53
  • Philip T., Armitage J. O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation alter failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1987; 316: 1493–1498
  • Phillips G. L., Fay J. W., Herzig R. H., et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1990; 75: 831–838
  • Petersen F. B., Appelbaum F. R., Hill R., et al. Autologous bone marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J. Clin. Oncol. 1990; 8: 638–647
  • Colombat P., Gorin N.-C, Lemonnier M.-P., et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 1990; 8: 630–637
  • Gribben J. G., Goldstone A. H., Linch D. C., et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still responsive to conventional dose chemotherapy. J. Clin. Oncol. 1989; 7: 1621–1629
  • Freedman A. S., Takvorian T., Anderson K. C., et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J. Clin. Oncol. 1990; 8: 784–791
  • Lazarus H. M., Crilley P., Ciobanu N., et al. High-dose carmustine. etoposide. and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J. Clin. Oncol. 1992; 10: 1682–1689
  • Appelbaum F. R., Sullivan K. M., Buckner C. D., et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J. Clin. Oncol. 1987; 5: 1340–1347
  • Chopra R., Goldstone A. H., Pearce R., et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data. J. Clin. Oncol. 1991; 10: 1690–1695
  • Hurd D. D., Le Bien T. W., Lasky L., et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am. J. Med. 1988; 85: 829–834
  • Schouten H. C., Bierman P. J., Vaughan W. P., et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood. 1989; 74: 2579–2584
  • Freedman A. S., Ritz J., Neuberg D., et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524–2529
  • Horowitz M. M., Rowlings P. A. Unpublished observations of the North American Autologous Bone Marrow Transplant Registry. 1993
  • Bierman P., Vose J., Armitage J., et al. High-dose therapy followed by autologous hematopoietic rescue for follicular low grade non-Hodgkin's lymphoma (NHL) (abstract #1074). Proc. Am. Sot: Clin. Oncol., 11: 317
  • Vose J. M., Bierman P. J., Anderson J. R., et al. High-dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin's lymphoma: evaluation of event-free survival based on histologic subtype and rescue product. Proc. Am. Sot: Clin. Oncol. 1992; 11: 318
  • Weisdorf D. J., Haake R., Miller W. J., et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotyping and in vitro purging. Bone Marrow Transplant, 8: 135–142
  • Simon R., Durrleman S., Hoppe R. T., et al. The Non-Hodgkin Lymphoma Pathologic Classification Project: Long-term follow-up of 1153 patients with non-Hodgkin's lymphomas. Ann. Intern. Med. 1988; 109: 939–945
  • Anderson T., Chabner B. A., Young R. C., et al. Malignant lymphoma. I. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2699–2707
  • Jones S. E., Fuks Z., Bull M., et al. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer 1973; 31: 806–823
  • Bearman S. I., Appelbaum F. R., Back A., et al. Regimenrelated toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J. Clin. Oncol. 1989; 7: 1288–1294
  • To L. B., Roberts M. M., Haylock D. N., et al. Comparison of haematologic recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992; 9: 277–284
  • Haas R., Ho A. D., Bredthauer U., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp. Hematol. 1990; 18: 94–98
  • Kessinger A., Armitage J. O. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood. 1991; 77: 211–213
  • Kessinger A., Vose J. M., Bierman P. J., Armitage J. O. High-dose chemotherapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging. Exp. Hematol. 1991; 19: 1013–1016
  • Vose J. M., Bierman P. J., Armitage J. O. High dose chemotherapy with stem cell rescue for the treatment of follicular low grade non-Hodgkin's lymphoma. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger. University of Nebraska Medical Center Press, Omaha 1991; 479–485
  • Körbling M., Holle R., Haas R., et al. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J. Clin. Oncol. 1990; 8: 978–985
  • Pecego R., Hill R., Appelbaum F. P., et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515–517
  • Phillips G. L., Wolff S. N., Herzig R. H., et al. The treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1989; 73: 2086–2092
  • Foucar K., McFenna R. W., Frizzera C., et al. Incidence and patterns of bone marrow involvement by lymphoma in relation to the Lukes-Collins classification. Blood 1979; 54: 1417–1422
  • Rosenberg S. A. Bone marrow involvement in the non-Hodgkin's lymphomata. Br. J. Cancer, (suppl 2) 1975; 31: 261–264
  • Stein R. S., Ultmann J. E., Byrne G. E., et al. Bone marrow involvement in non-Hodgkin's lymphoma: implications for staging and therapy. Cancer 1976; 37: 629–636
  • Chabner B. A., Johnson R. E., Young R. C., et al. Sequential nonsurgical and surgical staging on non-Hodgkin's lymphoma. Ann. Intem. Med. 1976; 85: 149–154
  • Smith B. R., Weinberg D. S., Robert N. I., et al. Circulating monoclonal B lymphocytes in non-Hodgkin's lymphoma. N. Engl. J. Med. 1984; 311: 1476–1481
  • Nakano M., Kawanishi Y., Kuge S., et al. Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B-cell lymphomas. Blood 1992; 79: 3253–3260
  • Bortin M. M., Horowitz M. M., Rimm A. A. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988–1990 survey. Ann. Intern. Med 1992; 116: 505–512
  • Gale R. P., Bortin M. M., van Bekkum D. W., et al. Risk factors for acute graft-versus-host disease. Br. J. Haematol. 1987; 67: 397–406
  • Atkinson K., Horowitz M. M., Gale R. P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464
  • Jones R. J., Ambinder R. F., Piantadosi S., Santos G. W. Evidence of a graft-versus-lymphomaeffect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653
  • Goldman J. M., Johnson S. A., Catovsky D., et al. Identical twin marrow transplantation for patients with leukemia and lymphoma. Transplantation 1981; 31: 140–141
  • Lu C., Braine H. G., Kaizer H., et al. Preliminary results of highdose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat. Rep. 1984; 68: 711–717
  • Appelbaum F. R., Thomas E. D., Buckner C. D., et al. Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogeneic marrow transplantation. Hematol. Oncol. 1983; 1: 149–157
  • Copelan E. A., Kapoor N., Gibbins B., Tutschka P. J. Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplantation 1990; 5: 47–50
  • Appelbaum F. R., Fefer A., Cheever M. A., et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 1981; 58: 509–513
  • Goldstone A. H., Pearce R., Personal communication
  • Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237–238
  • Limpins J., de Jong D., van Krieken J. H. J. M., et al. Bcl-2/Jh rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271–2276
  • Brenner M. K., Rill D. R., Moan R. C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993; 341: 85–86
  • Brenner M. K., Rill D. R. Gene marking to improve the outcome of autologous bone marrow transplantation. J. Hematother. 1994; 3: 33–36
  • Alperi M. A., Lopez M., Douay L., et al. Clonogenic leukemic progenitor cells in acute myelocytic leukemia are highly sensitive to cryopreservation: possible purging effect for autologous bone marrow transplantation. Bone Marrow Transplant 1991; 7: 101–105
  • Price C. G. A., Meerabux J., Murtagh S., et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J. Clin. Oncol. 1991; 9: 1527–1532
  • Goldstone A. H. Unpublished observations of the European Bone Marrow Transplant Registry. Presented at the First Annual Meeting of the North American Autologous Bone Marrow Transplant Registry, Keystone, Colorado, 1992
  • Gribben J. G., Freedman A. S., Neuberg D., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 1991; 325: 1525–1533
  • Weiss L. M., Warnke R. A., Sklar J., Cleary M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med 1985; 317: 1185–1189
  • Yunis J. J., Oken M. M., Kaplan M. E., et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N. Engl. J. Med 1982; 307: 1231–1236
  • Ngan B. Y., Nourse J., Cleary M. L. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73: 1759–1762
  • Gribben J. G., Freedman A. F., Woo S. D., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable bcl-2 translocation have residual cells containing the bcl-2 rearrangement at evaluation and following treatment. Blood 1991; 78: 3275–3280
  • European Bone Marrow Transplant Registry. Randomized trial in low-grade non-Hodgkin's lymphoma: purge vs no purge. 1993
  • Freedman A. S., Ritz J., Anderson K. C., . Autologous bone marrow transplantation in low grade B cell non-Hodgkin's lymphoma. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger, et al. University of Nebraska Medical Center Press, Omaha 1991; 453–463
  • Rohatiner A. Z. S., Price C. G. A., Amott S., . Ablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger, et al. University of Nebraska Medical Center Press, Omaha 1991; 465–471
  • Rohatiner A. Z. S., Lister T. A. Myeloablative therapy for follicular lymphoma. Hematol. Oncol. Clin. NA 1991; 5: 1003–1012
  • Rohatiner A. Z. S., Freedman A., Nadler I., et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma (abstract #38). Proceedings of the 5th International Conference on Lymphoma, LuganoSwitzerland, 1993
  • Vose, J. Personal communication. Data presented at the 6th International Symposium on Autologous Bone Marrow Transplantation, Houston, Texas, 1992
  • Colombat P., Biron P., Binet C., . High dose chemotherapy with autologous bone marrow transplantation in low grade non-Hodgkin's lymphomas. Autologous Bone Marrow Transplantation. IV. Proceedings of the Fourth International symposium, K. A. Dicke, G. Spitzer, S. Jagannath, M. J. Evinger Hodges, et al. The University of Texas. M. D. Anderson Cancer Center, Houston 1989; 317–325
  • Colombat P., Desbois I., Biron P., et al. Results of high dose chemotherapy with autologous bone marrow transplantation in 16 cases of follicular lymphoma (abstract). Exp. Hematol. 1989; 17: 585
  • Horning S. J. 1993, Personal communication
  • Fouillard L., Gorin N., Laporte I., et al. Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma. Eur. J. Haematol. 1991; 46: 279–284
  • Fouillard L., Gorin N. C., Laporte J. P., . A possible new approach to the management of follicular non-Hodgkin's lymphoma: early autologous bone marrow transplantation for consolidation in first remission. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger, et al. University of Nebraska Medical Center Press, Omaha 1991; 473–478
  • Higuchi C. M., Thompson J. A., Cox T., et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematologic malignancies. Cancer Res. 1989; 49: 5509–5513
  • Reittie J. E., Gottlieb D., Heslop H. E., et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
  • Klingemann H.-G., Phillips G. L. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 73–81
  • Ascensao J. L., Miller K. B., Tuck D., et al. Immunotherapy with recombinant human interferon alpha 2B (IFN) following autologous bone marrow transplantation (ABMT) for lymphomas: an update (abstract #1296). Proc. Am. Soc. Clin. Oncol. 1993; 12: 380
  • Schenkein D. P., Dixon P., Ascensao J. L., et al. Autologous bone marrow transplantation using cyclophosphamide, carboplatin, etoposide with post-transplant α interferon for patients with Hodgkin's and non-Hodgkin's lymphoma. Proc of the 5th International Conference on Lymphoma, LuganoSwitzerland, 1993
  • Klingemann H.-G, Grigg A. P., Wilkie-Boyd K., et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood. 1991; 78: 3306–3311
  • Nagler A., Ackerstein A., Or R., et al. Immunotherapy by recombinant alpha interferon (αIFN) and recombinant human in-terleukin-2(IL-2) of lymphoma patients post-autologous bone marrow transplantation (ABMTK)(abstract #262). Blood 1992; 80: 68a
  • Heslop H. E., Gottleib D. J., Bianchi A. C., et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374–1380
  • Blaise D., Olive D., Stoppa A. M., et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
  • Gottlieb D. J., Brenner M. K., Heslop H. E., et al. A phase I clinical trial of recombinant interleukin-2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer 1989; 60: 610–615
  • Gottlieb D. J., Prentice H. G., Heslop H. E., et al. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemoradiotherapy for hematologic malignancy. Blood. 1989; 74: 2335–2342
  • Higuchi C. M., Thompson J. A., Petersen F. B., et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood. 1991; 77: 2561–2568
  • Benyunes M., York A., Lindgren C., et al. 1L-2 LAK cells as consolidative therapy after autologous BMT for hematologic maligancies: a feasibility trial (abstract #1082). Proc. Am. Soc. Clin. Oncol. 1992; 11: 319
  • Larsson E. L., Joki A. L., Stalhandske T. Mechanism of action of the new immunomodulator LS26I6 on T cell-responses. Int. J. Immunopharmacol 1987; 9: 425–431
  • Bengtsson M., Simonsson B., Carlsson K., et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1982; 53: 882–888
  • Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 1990; 144: 442–476
  • Smalley R. V., Andersen J. W., Hawkins M. J., et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1336–1341
  • Horning S. J., Merigan T. C., Known S. E., et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease: results of the American Cancer Society trial. Cancer 1985; 56: 1305–1310
  • Foon K. A., Roth M. S., Bunn P. A., Jr. Alpha interferon treatment of low grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin. Oncol. 1986; 13(Suppl 2)35–42
  • Vander Molen L. A., Steis R. G., Duffey P. L., et al. Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 1990; 82: 235–238
  • Carella A. M., Gaozza E., Congin A., et al. Cyclosporineinduced graft-versus-host disease after autologous bone marrow transplantation in hematologic malignancies. Ann. Hematol 1991; 62: 156–159
  • Jones R. J., Vogelsang G. B., Hess A. D., et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; i: 754–757
  • Talbot D. C., Powles R. L., Sloane J. P., et al. Cyclosporineinduced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukemia. Bone Marrow Transplant. 1990; 6: 17–20
  • Yeager A. M., Vogelsang G. B., Jones R. J., et al. Induction of cutaneous graft-versus-dose disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031–3035
  • Kennedy M. J., Vogelsang G. B., Beveridge R. A., et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. 1993; 11: 478–484
  • Grossbard M. L., Freedman A. S., Ritz J., et al. Serotherapy of B cell neoplasms with anti-B4 blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79: 576–585
  • Grossbard M. L., Press O. W., Appelbaum F. R., et al. Perspective. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–878
  • Mertlesmann R., Herrmann F., Hecht T., Schulz G. Review. Hematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant 1990; 6: 79–87
  • Aurer I., Ribas A., Gale R. P. Review. What is the role of recombinant colony-stimulating factor in bone marrow transplantation?. Bone Marrow Transplant 1990; 6: 79–87
  • Lazarus H. M., Andersen J., Chen M. G., et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Group trial. Blood 1991; 78: 830–837
  • Nemunaitis J., Rabinowe S. N., Singer J. W., et al. Recombinant granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for lymphoid cancer. N. Engl J. Med. 1991; 324: 1773–1778
  • Gorin N. C., Coiffier B., Hayat M., et al. RHU GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study (abstract). Bone Marrow Transplant 1991; 7(Suppl 2)82
  • Gianni A. M., Tarella C., Siena S., et al. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant. 1990; 6: 143–145
  • Sheridan W. P., Begley C. G., Juttner C. A., et al. Effect of peripheral-blood progenitor cells mobilized by Filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644
  • Peters W. P., Rosner G., Ross M., et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
  • Chao N. J., Schriber J. R., Grimes K., et al. Granulocyte colony stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
  • Kotasek D., Shepherd K. M., Sage R. E., et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17
  • Brügger W., Brass K., Frisch J., et al. Mobilization of peripheral blood progenitor cells by sequential administration of in-terleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992; 79: 1193–1200
  • Korbling M., Hans M. Transplantation of Hemapheresis-derived hemopoietic stem cells: a new concept in the treatment of patients with malignant lymphohemopoietic disorders. Plasma Titer. Transfus. Technol. 1988; 9: 119–132
  • Ross A. A., Cooper B. W., Lazarus H. M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–2610
  • Moss T. J., Sanders, Lasky D. U., L C., et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879–1883
  • Sharp J. G., Armitage J., Crouse D., . Are occult tumor cells present in peripheral stem cell harvests of candidates for autologous transplantation?. Autologous Bone Marrow Transplantation. IV. Proceedings of the Fourth International Symposium, K. A. Dicke, G. Spitzer, S. Jagannath, M. I. Evinger-Hodges, et al. The University of Texas, M. D. Anderson Cancer Center, Houston 1989; 693–696
  • Körbling M., Fliedner T. M., Holle R., et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (PABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343–349
  • Brice P., Marolleau J. P., Dombret H., et al. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. Bone Marrow Transplant 1992; 9: 337–342
  • Brugger W., Brass K. J., Giant M., Weber F., Mertelsmann R., Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–640
  • Robbins R. A., Linder J., Stahl M. G., et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am. J. Med. 1989; 87: 511–518
  • Metcalf J. P., Rennard S. I., Reed E. C., et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. Am. J. Med. 1994; 96: 327–334
  • Juckett M., Perry E. H., Daniels B. S., Weisdorf D. J. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1991; 7: 405–409
  • Guinan E. C., Tarbell N. J., Niemeyer C. M., et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72: 451–455
  • Vose J., Darrington D., Bierman P., et al. Myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) following high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancy: characterization and relative risk (abstract #42). Proceedings of the 5th International Conference on Lymphoma, LuganoSwitzerland, 1993
  • Armitage J., Vose J., Anderson J., et al. Complete remission (CR) following high-dose chemotherapy (HDC) and autologous hematopoietic rescue for non-Hodgkin's lymphoma (NHL): evaluation of CR durability and incidence of secondary myelodysplastic syndrome (abstract # 1225). Proc. Am. Sot: Clin. Oncol. 1993; 12: 363
  • Saven A., Piro L. D. The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies. Cancer 1993; 72(suppl 11)3470–3483
  • Zinzani P. L., Lauria F., Rondelli D., et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann. Oncol. 1993; 4: 575–578
  • Whelan J. S., Davis C. L., Rule S., et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy, fir. J. Cancer 1991; 64: 120–123
  • Hiddemann W., Unterhalt M., Pott C., et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin. Oncol. 1993; 20 (suppl 7): 28–31
  • Hochster H. S., Kim K. M., Green M. D., et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 1992; 10: 28–32
  • Redman J. R., Cabanillas F., Velasquez W. S., et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794
  • O'Dwyer P. J., Wagner B., Leyland-Jones B., Wittes R. E., Cheson B. D., Hoth D. F. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rationale development of an active new drug. Ann. Intern. Med. 1988; 108: 733–743
  • O'Dwyer P. J., Cheson B. D., Leyland-Jones B., et al. Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia. Oncology 1988; 2: 17–27
  • Cummings F. J., Kim K., Neiman R. S., et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J. Clin. Oncol. 1991; 9: 565–571
  • Saven A., Piro L. D. 2-chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann. Intern. Med. 1994; 120: 784–791
  • Kay A. C., Saven A., Carrera C. J., et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 1992; 10: 371–377
  • Homing S. J. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.